Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-514 in Viremic Chronic Hepatitis B
NCT04470388Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of EDP-514 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Enanta Pharmaceuticals. Primary endpoint: Safety measured by adverse events up to 84 Days. Started Sep 2020; status: completed.
02
Drugs
EDP-514
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04470388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04470388.